Sunshine Biopharma, Inc. (NASDAQ:SBFM) Stock Short Interest Report for October

Sunshine Biopharma, Inc. (NASDAQ:SBFM) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 840,899 shares, a growth of 539.6% from the September 30th total of 131,478 shares. Currently, 19.8% of the shares of the stock are short sold. Based on an average trading volume of 28,786,521 shares, the short-interest ratio is currently 0.0 days.

Sunshine Biopharma Trading Up 22.0%

SBFM stock traded up $0.58 during mid-day trading on Tuesday, hitting $3.23. 190,822 shares of the company were exchanged, compared to its average volume of 113,583. Sunshine Biopharma has a twelve month low of $2.58 and a twelve month high of $464.00. The firm has a fifty day simple moving average of $15.74 and a 200 day simple moving average of $114.66. The company has a market capitalization of $13.94 million, a PE ratio of -0.32 and a beta of 1.20.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($23.00) EPS for the quarter, topping analysts’ consensus estimates of ($24.00) by $1.00. Sunshine Biopharma had a negative return on equity of 26.36% and a negative net margin of 17.94%. The firm had revenue of $9.26 million during the quarter, compared to the consensus estimate of $8.70 million. As a group, sell-side analysts anticipate that Sunshine Biopharma will post -1.95 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised Sunshine Biopharma to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings lowered Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a pharmaceutical and biotechnology company focused on developing and commercializing therapies for cancer and other medical conditions. The company’s research pipeline has included Adva-27a, an anticancer compound designed to target tumors that may be resistant to existing treatments, as well as mRNA-based therapeutic candidates.

Through its Canadian operations, including Nora Pharma, Sunshine Biopharma is also involved in the development, marketing and distribution of prescription and over-the-counter pharmaceutical products.